CD19-CAR-T2 cells / Southern Medical University - LARVOL DELTA

Targeted salvage therapy improves survival in B-ALL relapsing after CD19 CAR-T: A multi-institutional study (ASH 2025) - P=N/A, P1, P2 | "Patients with relapsed B-ALL following CD19 CAR-T therapy exhibit universally poor prognoses. Salvage therapies involving molecular targeting—including CAR-T reinfusion, monoclonal antibodies, and TKIs—demonstrate superior efficacy over salvage chemotherapy. These approaches provide critical opportunities for bridging to transplantation and improving overall survival."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • ABL1

Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement (ASH 2023) - P2 | "The cells were expanded ex vivo and administered in a single infusion (1×106 or 2×106 CAR T cells per kilogram of body weight) after a conditioning regimen of cyclophosphamide and fludarabine...Conclusion TLR2-costimulated CAR T cell therapy for patients with R/R B cell malignancies with CNS involvement is safe, feasible, and results in high response rates and durable remission in both ALL and NHL patients with CNS disease. The clinical trial was registered at www.clinicaltrials.gov as # NCT04605666."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • CNS Disorders • CNS Lymphoma • CNS Tumor • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • TLR2

CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies (clinicaltrials.gov) - P2 | N=77 | Completed | Sponsor: Nanfang Hospital, Southern Medical University | Recruiting ➔ Completed

CAR T-Cell Therapy • Trial completion • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Nanfang Hospital of Southern Medical University | Trial completion date: Jun 2021 ➔ Dec 2023 | Trial primary completion date: Dec 2020 ➔ Jun 2023

CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD19

CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P2; N=60; Recruiting; Sponsor: Nanfang Hospital of Southern Medical University

New P2 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology